ATHA

Stats

Summary

m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer

Market Cap: 149 Million

Primary Exchange: NASDAQ

Website: m3bio.com

Shares Outstanding: 38.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.140132460605096

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 1069 trading days

From: 2020-12-23 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor